The AT-rich region between -54 to -66 is important for the promoter activity of interleukin-10 in Epstein-Barr virus positive Burkitt's lymphoma cells

Genes and Immunity

Volumn 1, Issue 2, 1999, Pages 105-114

  Kube, D ^a,b   Laser, H ^a   Von Knethen, A ^a,c   Tesch, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Burkitt's lymphoma; EBV; Interleukin 10 promoter

Indexed keywords

HUMAN HERPESVIRUS 4;

INTERLEUKIN 10; OLIGONUCLEOTIDE;

ARTICLE; AT RICH SEQUENCE; BURKITT LYMPHOMA; CELL CULTURE; ENHANCER REGION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; PHYSIOLOGY; POINT MUTATION; PROMOTER REGION; VIROLOGY;

AT RICH SEQUENCE; BURKITT LYMPHOMA; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-10; OLIGONUCLEOTIDES; POINT MUTATION; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033224341     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363641     Document Type: Article

References (52)

1. Moore KW, O'Garra A, de WMR Vieira P et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
2. Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production and function. Methods 1997; 11: 98-111.
3. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG and de Fries VJ. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
4. Cassatella MA. The neutrophil: one of the cellular targets of interleukin-10. Int J Clin Lab Res 1998; 28: 148-161.
5. Burdin N, Van KC, Galibert L et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995; 154: 2533-2544.
6. Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-1893.
7. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045-4051.
8. Masood R, Zhan Y, Bond MW et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995; 85: 3423-3430.
9. Baiocchi RA, Ross ME, Tan JC et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995; 85: 1063-1074.
10. Stasi R, Zinzani PL, Galieni P et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770-777.
11. Blay JY, Burdin N, Rousset F et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169-2174.
12. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516-2520.
13. Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 1993; 177: 295-304.
14. Finke J, Ternes P, Lange W, Mertelsmann R, Dolken G. Expression of interleukin 10 in B lymphocytes of different origin. Leukemia 1993; 7: 1852-1857.
15. Klein SC, Kube D, Abts H, Diehl V, Tesch H. Promotion of IL8, IL10, TNFalpha and TNFbeta production by EBV infection. Leukemia Res (UK) 1996; 20: 633-636.
16. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994; 57: 240-244.
17. Kube D, Platzer C, von Knethen A et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995; 7: 1-7.
18. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997; 46: 120-128.
19. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 1995; 7: 517-523.
20. Eskdale J, Gallagher G, Verweij Cor L, Keijsers V, Westendorp Rudi GJ, Huizinga Tom W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
21. Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD. Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 1996; 26: 1580-1586.
22. Ohmori Y, Fukumoto S, Hamilton TA. Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J Immunol 1995; 155: 3593-3600.
23. Hou J, Baichwal V, Cao Z. Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1994; 91: 11641-11645.
24. Meyer CF, Wang X, Chang C, Templeton D, Tan TH. Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation. J Biol Chem 1996; 271: 8971-8976.
25. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992; 80: 1289-1298.
26. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo J (UK) 1998; 17: 1700-1709.
27. Zimber SU, Kempkes B, Marschall G et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. Embo J (UK) 1996; 15: 7070-7078.
28. Wang F, Gregory C, Sample C et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990; 64: 2309-2318.
29. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150-9154.
30. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997; 94: 1447-1452.
31. Mosialos G, Birkenbach M, Yalamanchili R, Van AT, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
32. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. Embo J 1997; 16: 6478-6485.
33. Devergne O, Hatzivassiliou E, Izumi KM et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (US) 1996; 16: 7098-7108.
34. Huen DS, Henderson SA, Croom CD, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995; 10: 549-560.
35. Mitchell T, Sudgen B. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of EBV. J Virol 1995; 69: 2968-2972.
36. Mori N, Gill PS, Mougdil T, Murakami S, Eto S, Prager D. Interleukin-10 gene expression in adult T-cell leukemia. Blood 1996; 88: 1035-1045.
37. Gires O, Zimber-Strobl U, Gonnella R et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. Embo J (UK) 1997; 16: 6131-6140.
38. Hatzivassiliou E, Miller WE, Raab TN, Kieff E, Mosialos G. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappaB, and stress-activated protein kinase. J Immunol (US) 1998; 160: 1116-1121.
39. Bucher P. Weight matrix description of eucaryotic RNA-polymerase II promoter elements. J Mol Biol 1990; 212: 563-578.
40. Corden J, Wasylyk B, Buchwalder A, Sassone CP, Kedinger C, Chambon P. Promoter sequences of eukaryotic protein-coding genes. Science 1980; 209: 1406-1414.
41. Guarente L. Transcriptional coactivators in yeast and beyond. Trends Biochem Sci 1995; 20: 517-521.
42. Javahery R, Khachi A, Lo K, Zenzie GB, Smale ST. DNA sequence requirements for transcriptional initiator activity in mammalian cells. Mol Cell Biol 1994; 14: 116-127.
43. O'Shea GA, Smale ST. Roles of TATA and initiator elements in determining the start site location and direction of RNA polymerase II transcription. J Biol Chem 1992; 267: 1391-1402.
44. Smale ST, Schmidt MC, Berk AJ, Baltimore D. Transcriptional activation by Sp1 as directed through TATA or initiator: specific requirement for mammalian transcription factor IID. Proc Natl Acad Sci USA 1990; 87: 4509-1513.
45. Yant SR, Zhu W, Millinoff D, Slightom JL, Goodman M, Gumucio DL. High affinity YY1 binding motifs: identification of two core types (ACAT and CCAT) and distribution of potential binding sites within the human beta globin cluster. Nucl Acids Res 1995; 23: 4353-4362.
46. Hyde Deruyscher RP, Jennings E, Shenk T. DNA binding sites for the transcriptional activator/receptor YY1. Nucl Acids Res 1995; 23: 4457-4465.
47. Mobley CM, Sealy L. Role of the transcription start site core region and transcription factor YY1 in Rous sarcoma virus long terminal repeat promoter activity. J Virol 1998; 72: 6592-6601.
48. Klug J, Beato M. Binding of YY1 to a site overlapping a weak TATA box is essential for transcription from the uteroglobin promoter in endometrial cells. Mol Cell Biol 1996; 16: 6398-6407.
49. Liljeholm S, Hughes K, Grundström T, Brodin P. NF-kB only partially mediates Epstein-Barr virus latent membrane protein 1 activation of B cells. J Gen Virol 1998; 79: 2117-2125.
50. Kube D, Vockerodt M, Haier B, Buttgereit P, Tesch H. IL-10 is induced by the Epstein-Barr virus LMP1 in Burkitt's lymphoma but not in Hodgkin cell lines. The C-terminal activation regions of LMP1 are neccessary but not sufficient to induce IL-10 (submitted for publication).
51. Beyaert R, Cuenda A, Vanden Berghe W et al. The p38/RK mitogen-activated kinase regulates IL-6 synthesis in response to TNF. EMBO J 1996; 15: 1914.
52. Wesselborg S, Bauer M, Vogt M, Schmitz M, Schulze-Osthoff K. Activation of transcription factor NFκB and p38 mitogen activated kinase is mediated by distinct and separate stress effector pathways. J Biol Chem 1997; 272: 12422-12429.